The below learning objectives are for the overall 2023 Annual Antimicrobial Stewardship Meeting. Session-specific learning objectives can be found on the agenda. Upon completion of the program learners will be able to:

  • Develop a strategy to evaluate and reduce health disparities in antimicrobial use in individual practice settings
  • Identify patients who may benefit from Beta-lactam TDM,
  • Discuss approaches to launch or expand an antibiotic stewardship program in a community hospital
  • Discuss evidence-based educational techniques and their application to infectious diseases education
  • Design a plan for improving antimicrobial stewardship in an intensive care setting
  • Explain factors contributing to inappropriate antibiotic use in outpatient settings
  • List potential barriers to implementing Gram-negative treatment guidance
  • Outline strategies for antibiotic stewardship programs to collaborate with clinical laboratories on diagnostic stewardship efforts 
  • Discuss clinical, social, and regulatory factors impacting future antibiotic use and resistance trends
  • Describe a framework for combatting emerging antimicrobial resistance threats in the future
  • Define de-escalation in terms of spectrum, route, and duration of therapy
  • Describe the gaps in antibiotic and immunomodulatory therapy development
  • Describe the latest recommendations for the treatment of Gram-negative non-fermenters
  • Identify the therapeutic gaps in guidelines associated with treatment of Staphylococcus aureus infections
  • Discuss the history, development, and utility of Antimicrobial Susceptibility Testing methodologies
  • Describe the approaches used to develop susceptibility interpretive criteria in different agencies (e.g. CLSI, FDA, USCAST, EUCAST)
  • Identify emerging technologies for rapid microbial identification and susceptibility testing in inpatient and outpatient settings
  • Describe the importance of collaboration between antibiotic stewardship programs and internal medicine and other clinicians                    
  • Outline recent updates to CDC ACIP vaccine recommendations and their supporting clinical evidence 
  • Discuss the importance of the microbiome and fecal microbiota transplantation in prevention of C. difficile infection and recent updates on evaluation and management of C. difficile infection
  • Identify major developments published in the ID literature from May 2022 thru April 2023